Randomized comparison of fluorouracil plus cisplatin vs. cisplatin as an adjunct to radiation therapy in stage IIB-IVA squamous cell carcinoma of the cervix: pilot study.
OBJECTIVE
To compare the efficacy and toxicity of pelvic radiotherapy with concomitant cisplatin plus fluorouracil versus cisplatin alone in patients with locally advanced squamous cell cervical cancer.


METHODS
Twenty women with squamous cell cervical cancer were randomly assigned to receive ether standard whole pelvic radiotherapy with concurrent cisplatin and fluorouracil infusion every 4 weeks or the same radiotherapy with concurrent cisplatin every 1 week. The primary endpoint was the response rate.


RESULTS
All patients in cisplatin plus fluorouracil regimen and in cisplatin regimen had complete response. In cisplatin group there was higher frequencies of adverse hematologic effects. Grade 3 or 4 neutropenia occurred in 10% of the cisplatin plus fluorouracil group and in 40% of the cisplatin group (p = 0.049).


CONCLUSIONS
No difference was found in the response rate, but higher frequencies of hemotological adverse effects in the cisplatin group.
Sukhaboon
Jirasak
J
Department ofTherapeutic Radiology, Udonthani Cancer Center, Udon Thani, Thailand. Fodjiji@yahoo.com
Porapakkhan
Patchaneeporn
P
Penpattanagul
Somkit
S
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced; D010865:Pilot Projects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
D000964:Antimetabolites, Antineoplastic; D002945:Cisplatin; D005472:Fluorouracil